Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HPV vaccine approval

This article was originally published in The Gray Sheet

Executive Summary

Introduction of Merck's human papillomavirus vaccine Gardasil will not change the need for Pap or HPV screening, says Digene, which manufacturers the only diagnostic approved by FDA as an adjunct to the Pap test for primary cervical cancer screening. The vaccine is "not a magic bullet for eliminating cervical cancer," Digene says, because it does not protect against all strains of HPV and it is not appropriate for all populations of women. FDA approved the vaccine June 8 for use in girls and women ages 9 to 26. Digene hopes to leverage Merck's vaccine promotions to boost sales of its hc2 High-Risk HPV DNA Test (1"The Gray Sheet" May 15, 2006, p. 12)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel